NovoCure NVCR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 74.5%-2.8pp | 77.3%+2.5pp | 74.8%-3.8pp | 78.6%+0.1pp | |
| Operating margin | -23.5%+4.7pp | -28.2%+17.5pp | -45.7%-29.1pp | -16.6%-8.4pp | |
| Net margin | -20.8%+7.1pp | -27.9%+12.8pp | -40.6%-23.4pp | -17.2%-6.3pp | |
| EBITDA margin | -21.2%+5.1pp | -26.3%+17.3pp | -43.6%-28.9pp | -14.7%-8.3pp | |
| Free cash flow margin | -11.5%-0.1pp | -11.4%+8.3pp | -19.7%— | —— | |
| Returns | |||||
| Return on equity | -38.9%+7.8pp | -46.7%+4.9pp | -51.5%-29.8pp | -21.7%-8.6pp | |
| Return on assets | -13.3%+0.8pp | -14.1%+3.6pp | -17.7%-9.8pp | -7.9%-2.6pp | |
| Return on invested capital | -58.6%-22.8pp | -35.9%-7.5pp | -28.4%-17.8pp | -10.5%-4.5pp | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.4×0.0× | 0.5×0.0× | |
| Inventory turnover | 4.4×+0.6× | 3.7×-0.1× | 3.8×-0.5× | 4.3×-0.2× | |
| Liquidity | |||||
| Current ratio | 2.9×+1.4× | 1.5×-4.3× | 5.8×-1.2× | 7×-0.5× | |
| Quick ratio | 2.7×+1.3× | 1.4×-4.1× | 5.6×-1.3× | 6.8×-0.5× | |
| Cash ratio | 0.4×+0.2× | 0.2×-1.1× | 1.3×+0.6× | 0.7×-0.7× | |
| Leverage | |||||
| Debt-to-equity | 0.2×+0.1× | 0.1×-1.6× | 1.7×+0.3× | 1.3×-0.1× | |
| Debt-to-assets | 0.1×0.0× | 0×-0.5× | 0.5×0.0× | 0.5×0.0× | |
| Interest coverage | -8.5×-4.2× | -4.3×+1.3× | -5.7×+0.1× | -5.8×— | |
| Per Share | |||||
| Book value per share | $3.05-8.6% | $3.34-2.0% | $3.41-18.9% | $4.20+6.3% | |
| Valuation | |||||
| Market capitalization | $1.45B-55.1% | $3.22B+102% | $1.6B-79.3% | $7.7B-1.2% | |
| Enterprise value | $1.41B-54.4% | $3.09B+57.5% | $1.96B-76.0% | $8.17B+0.1% | |
| Price / sales | 2.2×-3.1× | 5.3×+2.2× | 3.1×-11.2× | 14.3×-0.3× | |
| Price / book | 4.3×-4.7× | 9×+4.5× | 4.4×-13.0× | 17.4×-1.5× | |
| EV / sales | 2.1×-3.0× | 5.1×+1.3× | 3.8×-11.3× | 15.2×-0.1× | |
| Free cash flow yield | -5.2%-3.1pp | -2.1%+4.1pp | -6.3%— | —— | |
| Earnings yield | -9.4%-4.2pp | -5.2%+7.7pp | -13%-11.8pp | -1.2%-0.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NovoCure's profit margins?
- NovoCure (NVCR) runs a 75.2% gross margin and a -27.2% operating margin, with a -25.7% net margin.
- Where do NovoCure's ratios come from?
- Every ratio is computed from NovoCure's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.